Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase 2 Trial of Yttrium-90 Radiation Segmentectomy for Unresectable Hepatocellular Carcinoma

NCT07110233 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT07110233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07110233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase 2 Trial of Yttrium-90 Radiation Segmentectomy for Unresectable Hepatocellular Carcinoma
Lead sponsor
University of California, San Francisco
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
March 31, 2029
Enrollment
64 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular cancer, hepatocellular carcinoma, hepatocellular carcinoma non-resectable, unresectable hepatocellular carcinoma